Meconium Aspiration Syndrome (MAS)

Definition & Epidemiology

1. Delivery through meconium-stained amniotic fluid (MSAF)
2. Respiratory distress
3. Characteristic chest X-ray appearance

• MSAF occurs in 4–22% of all deliveries, more commonly in post-term pregnancies
• MAS complicates approximately 1–2% of deliveries with MSAF
• Most common in post-mature (post-term) infants; unusual before 36 weeks due to incomplete maturation of the intestinal myenteric plexus
• Approximately 30% of affected infants require mechanical ventilation

Pathophysiology

Chest X-Ray Findings

• Bilateral hyperinflation
• Asymmetrical coarse/patchy opacification (segmental atelectasis alternating with air-trapping)
• Air leaks (pneumothorax, pneumomediastinum) — common complication
• Small pleural effusions may be present
• Chemical pneumonitis pattern

Clinical Severity

• Need for positive-pressure ventilation
• Presence of pulmonary hypertension (PPHN)

• Air leak syndromes (pneumothorax)
• Chronic lung disease
• Developmental delay
• Death

Prevention

Antenatal

• Induction of labor at 41 weeks — systematic reviews show fewer MAS cases and fewer cesarean sections vs. expectant management
• Amnioinfusion to dilute thick meconium — did NOT reduce MAS incidence or perinatal morbidity in well-monitored settings

Peripartum Suctioning — Evolving Guidelines

Delaying positive-pressure ventilation (PPV) to suction may cause more harm than benefit. Skilled personnel for airway management should attend all expected depressed deliveries.

Treatment

Respiratory Support

• Positive-pressure ventilation for respiratory failure
• If vigorous and crying at birth → no suctioning needed; if depressed → intubate and suction if meconium present, then proceed with PPV if bradycardia develops

Pulmonary Hypertension (PPHN)

• Inhaled nitric oxide (iNO) — first-line; improves oxygenation and allows less injurious ventilation
• Sildenafil — oral PDE-5 inhibitor
• Bosentan — endothelin receptor antagonist

Surfactant

• Exogenous surfactant — early administration is a useful adjunct (counteracts surfactant inactivation by meconium)

Salvage Therapy

• ECMO (Extracorporeal Membrane Oxygenation) — for infants failing conventional treatment
  • VA-ECMO: cannulae via internal jugular vein + common carotid artery
  • VV-ECMO: double-lumen catheter via internal jugular vein
• Antibiotics and steroids — selectively used; no demonstrated effectiveness in trials

Key Takeaways

• MAS is distinct from simply having MSAF — requires respiratory distress + CXR findings
• Pathophysiology is multifactorial: obstruction + inflammation + surfactant inactivation + PPHN
• Routine tracheal suctioning is no longer recommended regardless of infant vigor — a major departure from historical practice
• iNO + surfactant are the cornerstones of treatment; ECMO is salvage
• Prognosis has improved dramatically with modern management

Persistent Pulmonary Hypertension of the Newborn (PPHN)

Definition & Epidemiology

• Incidence: ~2/1000 live births in term and late preterm infants
• Presents within the first 12–24 hours of birth
• One of the leading causes of neonatal morbidity and mortality

Normal Fetal-to-Neonatal Transition

• Effective clearance of lung fluid
• Lung aeration and oxygenation
• Ventilation
• Cord clamping → rise in systemic vascular resistance (SVR)
• Reversal of flow across the ductus arteriosus and foramen ovale

Causes & Classification

• Maternal SSRI or NSAID use (in utero ductal constriction)
• Maternal smoking, uncontrolled diabetes, asthma
• Cesarean section delivery, polycythemia, low Apgar scores

Pathophysiology

• Hypoxemia out of proportion to other clinical/radiologic findings
• Normal or elevated PaCO₂ (lungs not being perfused)
• The pulmonary circulation is exquisitely sensitive to hypoxia, acidosis, and inflammatory mediators, all of which perpetuate vasoconstriction

Diagnosis

Clinical Features

• Severe hypoxemia (PaO₂ <35–45 mmHg in 100% O₂)
• Pre-/postductal SpO₂ gradient ≥7–15 mmHg is significant (right hand preductal vs. lower extremity postductal)
• Structurally normal heart on echo — right-to-left shunt at foramen ovale and/or ductus arteriosus

Key Diagnostic Step

• Hyperoxia test: PaO₂ fails to rise significantly with 100% O₂ in both cyanotic CHD and PPHN
• Echocardiography is definitive — confirms structurally normal heart and shows direction of shunting

Treatment

General Principles

1. Optimize Oxygenation

• Supplemental oxygen — a potent pulmonary vasodilator
• Target preductal O₂ saturations (to reduce lung injury from overdistention)
• Correct polycythemia, hypoglycemia, metabolic disturbances

2. Minimize Pulmonary Vasoconstriction

• Minimal handling — noxious stimuli spike PVR; sedation (and occasionally paralysis in intubated infants) is important
• Avoid severe hyperventilation — hypocarbia (PCO₂ <30 mmHg) causes myocardial ischemia and decreased cerebral blood flow; can also lead to barotrauma
• Consider high-frequency oscillatory ventilation to limit lung injury

3. Maintain Systemic Blood Pressure

• Reversal of right-to-left shunt requires adequate SVR
• Volume expanders and/or inotropes (e.g., dopamine, dobutamine)
• Note: dobutamine may reduce SVR in normotensive patients — can paradoxically worsen R→L shunting but offloads the RV

4. Pulmonary Vasodilator Therapy

OI formula: OI = (Mean Airway Pressure × FiO₂ × 100) / PaO₂

5. ECMO (Salvage)

• OI >40 sustained for >3 hours, OR
• A-aO₂ gradient ≥610 for 8 hours
• Severe cardiovascular instability unresponsive to therapy

• Obtain head ultrasound (exclude IVH) and consider EEG before initiating
• iNO has not reduced the need for ECMO in CDH specifically

Prognosis

• Outcome varies directly with ability to reduce PVR and address the underlying cause
• Ischemic encephalopathy is a major negative prognostic factor
• Survivors of severe PPHN are at risk for neurodevelopmental impairment and chronic lung disease

Summary Flowchart

PPHN suspected (severe hypoxemia, pre/postductal gradient)
        ↓
Echo → rule out cyanotic CHD
        ↓
Treat underlying cause + optimize ventilation
        ↓
iNO (OI ≥15) ± adjuvant vasodilators
        ↓
OI >40 for >3h → ECMO evaluation

Infant of a Diabetic Mother (IDM) — Screening

Overview of Complications

Screening Protocol

1. Hypoglycemia Screening (Most Critical)

Initial feed should occur within ≤1 hour of birth for IDM infants.

2. Polycythemia Screening

• Check hematocrit/hemoglobin — polycythemia defined as venous Hct >65%
• Polycythemia → hyperviscosity → risk of stroke, NEC, renal vein thrombosis, PPHN

3. Electrolyte Screening

• Serum calcium (hypocalcemia: <7 mg/dL total or <4 mg/dL ionized)
• Serum magnesium (hypomagnesemia often accompanies hypocalcemia; correcting Mg is prerequisite to correcting Ca)
• Typically checked at 24–48 hours of life

4. Cardiac Screening

• Echocardiogram if clinically indicated — IDM has increased risk of:
  • Hypertrophic cardiomyopathy (asymmetric septal hypertrophy)
  • Structural CHD (TGA, VSD)
• Critical CHD screening: Pre- and postductal pulse oximetry before discharge (standard for all newborns, especially important in IDM)

5. Respiratory Assessment

• IDM has delayed surfactant maturation → monitor for RDS symptoms, especially in late preterm IDM
• Lung maturity at a given gestational age is less than in non-IDM infants — avoid elective delivery <39 weeks without documented lung maturity

6. Bilirubin Monitoring

• Polycythemia → increased RBC breakdown → hyperbilirubinemia
• Transcutaneous or serum bilirubin monitoring per standard risk assessment protocols

7. Standard Newborn Screens (All Infants)

• Newborn metabolic screen (PKU, congenital hypothyroid, etc.) — ≥24h after feeding, within 72h
• Hearing screen
• Red reflex examination
• Hepatitis B vaccine

Summary Screening Checklist for IDM

The key principle: most IDM complications are transient and resolve without long-term sequelae if identified and managed promptly. Neonatal morbidity is proportional to the degree of maternal glycemic control during pregnancy.